All News

4 May 2009

Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer PatientsAntibodies

30 April 2009

Enrollment Completed in Phase 1 Program for XOMA 052 in Type 2 DiabetesAntibodies

30 April 2009

Bayer and Regeneron extend development program for VEGF Trap-EyeAntibodies

27 April 2009

Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer TrialAntibodies

27 April 2009

Simponi™ (Golimumab) Receives FDA Approval As First Once-Monthly Anti-TNF For Treatment Of Rheumatoid Arthritis, Psoriatic ArthritisAntibodies

23 April 2009

Alethia Biotherapeutics Closes $2.2 M Financing – Proceeds to Advance Pre-Clinical Development of Lead Drug CandidatesAntibodies

23 April 2009

Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual MeetingAntibodies

23 April 2009

Fresenius Biotech receives approval for Removab® by European Commission – First Drug worldwide for Treatment of Malignant AscitesAntibodies

22 April 2009

Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine’s Fully Human Anti-PS Antibody in Prostate Cancer ModelAntibodies

22 April 2009

Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs at AACRAntibodies

22 April 2009

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in CancerAntibodies

22 April 2009

Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110Antibodies

22 April 2009

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer CellsAntibodies

22 April 2009

Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary EndpointAntibodies

21 April 2009

Seattle Genetics Highlights Dacetuzumab Preclinical Research at AACRAntibodies

21 April 2009

Lpath Scientists and Collaborators Present Favorable New Study Data of Leading Cancer Drug Candidate, ASONEP(TM)Antibodies

21 April 2009

Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile InfectionAntibodies

21 April 2009

Lpath Presents Compelling New Preclinical Results of Its Anti-Cancer Drug Candidate, Lpathomab(TM), at the AACR 100th Annual MeetingAntibodies

20 April 2009

AACR 100th Annual Meeting Highlights Superior Ability of InNexus’ DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical StudiesAntibodies

20 April 2009

Immunomedics Expands Product Pipeline for Potential Therapy of Cancer and Inflammatory DiseasesAntibodies

20 April 2009

Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer TrialAntibodies

20 April 2009

Medarex Announces Clinical Data for MDX-1401 in Hodgkin’s Lymphoma at Annual Meeting of the American Association for Cancer ResearchAntibodies

20 April 2009

AVEO Presents Novel HGF Model and Promising Preclinical Activity to Support Lead Antibody Agent SCH 900105 (AV-299)Antibodies

10 April 2009

ArmaGen plans First in Human clinical trialAntibodies

8 April 2009

Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. MarketAntibodies

8 April 2009

BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventisAntibodies

8 April 2009

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor GrowthAntibodies

6 April 2009

Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7Antibodies

6 April 2009

Seattle Genetics Announces Antibody-Drug Conjugate Collaboration With MillenniumAntibodies

3 April 2009

Arzerra (TM) (ofatumumab) granted priority review by FDAAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Adalimumab (Humira) Biosimilars Pipeline Review

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

FcRn Inhibitors Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

TROP-2-Targeted Immunotherapy Pipeline Review

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing